Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 mirikizumab trial in moderately to severely active Crohn's disease
MOH_2019-08-29_007371Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mirikizumab in Crohn's disease (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Endoscopic response at week 52 and Clinical remission by patient-reported outcomes at week 52. Started Jul 2019; status: active, not recruiting.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2019-08-29_007371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-29_007371.